2 terminated, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow UCB Celltech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome UCB5857, Placebo - Primary Sjögren's Syndrome | Phase 2 | Terminated | UCB Celltech | 27 | 2015-10-01 | 2020-12-01 |
| Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis Bimekizumab, Certolizumab Pegol, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | UCB Celltech | 159 | 2015-04-01 | 2017-05-31 |
| The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents Certolizumab Pegol - Crohn's Disease | Phase 2 | Terminated | UCB Celltech | 99 | 2009-04-01 | 2018-08-07 |
Arthritis, Rheumatoid (1) · Crohn Disease (1)
Certolizumab Pegol (2) · bimekizumab (1)
United Kingdom (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · Italy (1) · Moldova (1) · New Zealand (1) · Poland (1) · Russia (1) · Slovakia (1) · Spain (1) · Sweden (1) · United States (1)
2014 (3)